Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention ...

The new partnership combines Mainz Biomed's expertise in DNA-based diagnostics with labor team w's strong track record in ...

Fintel reports that on February 14, 2025, Maxim Group initiated coverage of Mainz Biomed N.V. (NasdaqCM:MYNZ) with a Buy recommendation. Analyst Price Forecast Suggests 66.00% Downside As of November ...

BERKELEY, Calif. and MAINZ, Germany, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed” or the "Company”), a molecular genetics diagnostic company specializing in the ...

Mainz Biomed partners with labor team to launch DNA-based ColoAlert® colorectal cancer screening in Switzerland, enhancing early detection efforts. Mainz Biomed N.V. has announced a strategic ...

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Lowering barriers to CRC screening is crucial in empowering both patients and healthcare professionals in early cancer detection. One key initiative is increasing accessibility through at-home testing ...

BERKELEY, Calif. and MAINZ, Germany, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics ...

BERKELEY, US – MAINZ, Germany – February 20, 2025 -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the“Company”), a molecular genetics diagnostic company specializing in the early ...